Why Losing Weight Does Not Always Fix PCOS: What Hormones, Insulin, and Inflammation Actually Do

The standard advice given to women with PCOS goes like this: lose 5 to 10 percent of your body weight and your symptoms will improve. That figure comes from real research. A 2007 study published in the New England Journal of Medicine by Legro and colleagues showed that weight reduction improved ovulation rates in women with PCOS. Clinicians ran with it. What got left out of the conversation was that a significant proportion of women in that and subsequent studies did not see cycle restoration even after sustained weight loss, and that roughly 20 percent of women diagnosed with PCOS are not overweight at all.

The Rotterdam criteria, the diagnostic standard used globally, require only two of three features: irregular ovulation, elevated androgen levels, or polycystic ovaries on ultrasound. Weight is not a criterion. A lean woman with regular periods but high testosterone and cystic ovaries qualifies. An overweight woman with normal androgens and regular cycles does not. PCOS is a hormonal diagnosis, not a body composition one.

Between 65 and 80 percent of women with PCOS have some degree of insulin resistance, regardless of their BMI. Indian women with PCOS show particularly high rates, research from the All India Institute of Medical Sciences has documented that South Asian women develop insulin resistance at lower BMI thresholds than Western populations, meaning the metabolic disruption begins earlier and at lower body weights.

When cells resist insulin, the pancreas compensates by producing more. Elevated insulin directly stimulates the ovaries to produce excess androgens, testosterone and DHEA-S, and suppresses a protein called sex hormone-binding globulin (SHBG) that would otherwise neutralise free testosterone. The result is a hormonal environment that prevents follicles from maturing and releasing eggs. Weight loss can reduce insulin levels, which is why it helps some women. But if the insulin resistance is structural, driven by genetics, chronic stress, or gut microbiome composition, calorie restriction alone does not fix the underlying receptor dysfunction.

This is why metformin, a drug that improves insulin sensitivity at the cellular level, has become a cornerstone of PCOS management in Indian gynaecology practice even for women who are not diabetic. It addresses the mechanism, not just the output.

Elevated androgens in PCOS cause acne, hair thinning at the crown, and excess facial or body hair. These symptoms are driven by the androgen-to-SHBG ratio, not by fat tissue directly. A woman who loses weight but whose SHBG remains suppressed, because insulin is still elevated, or because her liver is not producing enough SHBG, will continue to experience androgen-driven symptoms.

Chronic low-grade inflammation is a separate thread. Studies measuring C-reactive protein and interleukin-6 in women with PCOS consistently show elevated inflammatory markers independent of BMI. Inflammation worsens insulin resistance, which worsens androgen excess, which worsens follicle development. The cycle does not have a single entry point, and targeting only one, body fat, leaves the others running.

Inositol, specifically the myo-inositol and D-chiro-inositol combination, has accumulated strong trial evidence. A 2019 meta-analysis in the International Journal of Endocrinology found that inositol supplementation improved ovulation rates, reduced fasting insulin, and lowered androgen levels in women with PCOS. It works by improving insulin signal transduction at the receptor level, the same pathway metformin targets, through a different mechanism.

Strength training improves insulin sensitivity in skeletal muscle without requiring significant weight loss. The mechanism is GLUT4 transporter activation: muscle contraction moves glucose transporters to the cell surface, reducing the insulin load required to clear blood sugar. Two to three sessions per week of resistance training show measurable improvements in fasting insulin within eight to twelve weeks in PCOS populations.

Sleep quality matters more than most gynaecologists discuss. Cortisol dysregulation from poor sleep directly elevates insulin resistance the following morning. A single night of four hours of sleep raises fasting insulin by a clinically meaningful margin in healthy adults; in women with pre-existing insulin resistance, the effect compounds. Addressing cortisol through sleep and stress management is not a soft lifestyle suggestion, it is targeting a hormone that sits directly upstream of the PCOS cascade.

Anti-inflammatory dietary patterns, reducing refined carbohydrates, increasing omega-3 fatty acids, adding foods like flaxseed and walnuts, reduce the inflammatory markers that sustain insulin resistance. This is not the same as a weight-loss diet. The goal is reducing IL-6 and CRP, not a calorie deficit.

For women trying to conceive, the weight-first approach creates a particular problem: it delays treatment. Ovulation induction with letrozole is now preferred over clomiphene in PCOS-related infertility, based on a large multicentre trial published in the New England Journal of Medicine in 2014 by Legro and colleagues. Letrozole produced higher live birth rates than clomiphene regardless of BMI. Waiting for a woman to lose weight before initiating ovulation induction has no evidence base when the pharmacological option is available and effective across body types.

Fertility in PCOS is primarily an ovulation problem driven by hormones and insulin. Treating those directly, rather than waiting for a scale to reach a number, is what the evidence supports.

Weight is a downstream variable in PCOS, not the upstream cause. The women who improve after losing weight do so because the weight loss incidentally reduced their insulin levels and inflammation, but those same targets can be reached through resistance training, inositol, sleep, and anti-inflammatory eating without waiting for a specific number on a scale. The condition is hormonal. The treatment has to be too.